Drugs / AAVrh.10cuARSA
AAVrh.10cuARSA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01801709 | Jun 2014 → Jun 2016 | metachromatic leukodystrophy | French National Institute of Health and Medical Research | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAVrh.10cuARSA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01801709 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-associated Virus Gene Transfer Vector Serotype rh.10” NCT01801709 ↗ |
| Route | Other | “intracerebral administration of AAVrh.10cuARSA” NCT01801709 ↗ |
| Target | ARSA | “to transfer the ARSA cDNA coding for Arylsulfatase A (ARSA) enzyme into the brain of children” NCT01801709 ↗ |